- Home
- HI vs AKRO Comparison
HI vs AKRO Comparison
Compare HI & AKRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HI
- AKRO
- Stock Information
- Founded
- HI 2007
- AKRO 2017
- Country
- HI United States
- AKRO United States
- Employees
- HI N/A
- AKRO N/A
- Industry
- HI Miscellaneous manufacturing industries
- AKRO Biotechnology: Pharmaceutical Preparations
- Sector
- HI Consumer Discretionary
- AKRO Health Care
- Exchange
- HI Nasdaq
- AKRO Nasdaq
- Market Cap
- HI 2.4B
- AKRO 2.0B
- IPO Year
- HI N/A
- AKRO 2019
- Fundamental
- Price
- HI $33.94
- AKRO $25.14
- Analyst Decision
- HI Buy
- AKRO Strong Buy
- Analyst Count
- HI 2
- AKRO 8
- Target Price
- HI $36.50
- AKRO $46.83
- AVG Volume (30 Days)
- HI 426.3K
- AKRO 842.7K
- Earning Date
- HI 02-03-2025
- AKRO 02-27-2025
- Dividend Yield
- HI 2.63%
- AKRO N/A
- EPS Growth
- HI N/A
- AKRO N/A
- EPS
- HI N/A
- AKRO N/A
- Revenue
- HI $3,182,800,000.00
- AKRO N/A
- Revenue This Year
- HI N/A
- AKRO N/A
- Revenue Next Year
- HI $4.10
- AKRO N/A
- P/E Ratio
- HI N/A
- AKRO N/A
- Revenue Growth
- HI 12.63
- AKRO N/A
- 52 Week Low
- HI $25.11
- AKRO $15.32
- 52 Week High
- HI $50.58
- AKRO $37.00
- Technical
- Relative Strength Index (RSI)
- HI 67.20
- AKRO 41.89
- Support Level
- HI $30.25
- AKRO $21.34
- Resistance Level
- HI $31.79
- AKRO $28.94
- Average True Range (ATR)
- HI 0.83
- AKRO 1.38
- MACD
- HI 0.38
- AKRO -0.27
- Stochastic Oscillator
- HI 91.38
- AKRO 49.67
About HI Hillenbrand Inc
Hillenbrand Inc is a U.S.-based company that operates through two segments. The Advanced Process Solutions segment designs, develops, manufactures, and services engineered industrial equipment. The Molding Technology Solutions segment offers engineered and customized systems in plastic technology and processing. It earns it revenue from Advanced Process Solutions, and Geographically from America, following by Asia and EMEA.
About AKRO Akero Therapeutics Inc.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis, or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that has the potential to address the core processes underlying NASH pathogenesis.